announced the dosing of the first patient in its Phase 2 clinical trial, the HORIZON Study, which is investigating MZE829, an oral APOL1 inhibitor, for treating APOL1 kidney disease (AKD).

today announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease (AKD). MZE829 is an oral, small ...

Phase 1 study results indicate TNX-1500's potential for kidney transplant rejection prevention and support monthly dosing in future trials. Tonix Pharmaceuticals Holding Corp. announced positive ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene ...

In the open-label phase 2 LITESPARK-003 study ... which includes patients who have not yet received treatment for advanced kidney cancer. After a median follow up of 24 months, 70% of patients ...

Study Title: Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study Publication ...

With its potential to be a truly disease-modifying therapy, MZE829 represents hope for the many patients living with AKD, addressing a critical unmet need in kidney disease treatment.” The HORIZON ...

A chili bean is not any particular type of bean. Chili beans are typically kidney beans with added flavor, whereas kidney ...